Skip to main
BIOA

BIOA Stock Forecast & Price Target

BIOA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Bioage Labs is an attractive investment due to its focus on the biology of human aging and chronic inflammation, which are key areas of drug development. Their technology platform and human-aging data set adds a competitive advantage, and with a four-year cash runway and upcoming catalysts in 2026 and 2027 for their lead candidate, BGE-102, in cardiovascular and ocular disease, respectively, the company is poised for success. Additionally, the potential for their second drug, BGE-105, to have a strong synergy with weight loss drugs bodes well for their pipeline. While risks are inherent in the biotechnology industry, Bioage Labs' approach and potential make it a prime candidate for further growth.

Bears say

Bioage Labs is a clinical-stage biopharmaceutical company with high risks in the biotechnology sector due to potential regulatory, commercial, and partnership risks. Its lead program, BGE-102, is still in early development, with Phase 2 proof-of-concept data expected several years from now. The company also faces competitive pressure from better capitalized pharmaceutical giants in the same space, and its current valuation may not be fully justified by its limited product pipeline and potential for revenue generation in the near future.

BIOA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioAge Labs Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioAge Labs Inc. (BIOA) Forecast

Analysts have given BIOA a Buy based on their latest research and market trends.

According to 8 analysts, BIOA has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioAge Labs Inc. (BIOA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.